Welcome to the Stock of the Day. Wall Street may be jittery about a few ... Now that Amgen has acquired cancer drug specialist Onyx Pharmaceutical (ONXX), sales of Onyx’s myeloma drug Kyprolis alone are expected to add between …
The stock is trading at 98.5% of its 50-day moving average and 88.7% of its 200-day moving average. Onyx Pharmaceuticals (ONXX) experienced a price drop on above-average volume today, with 4.3 million shares, or 2.6 its …
Amgen, Inc. (AMGN): The world's biggest biotechnology firm, fresh from sealing a $10.4 billion deal to buy oncology powerhouse Onyx Pharmaceuticals Inc. (ONXX), is now Overweight ... James takes the transportation stock to Strong …
Fueling the fire was the proposed acquisition of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) by Amgen, Inc. (NASDAQ:AMGN) for a 38% premium. Onyx’s management rejected the proposal and put itself up for sale. The stock
BANGALORE, Feb 24 (Reuters) - Shares of Onyx Pharmaceuticals Inc ONXX.O were up more than 19 percent Tuesday ... Harr raised his price target on the stock to $23 from $21, but maintained an “underweight” rating on the stock. For the …
U.S. stock futures were slightly lower early Monday as investors ... Shares of Amgen (AMGN) rose 4% after it agreed to buy Onyx Pharmaceuticals (ONXX) for $10.4 billion, in a deal that will give Amgen access to a wide range of cancer …
Power Gauge Ratings are created using a relative ranking system that assigns a rank of 0 to 100 (100 being the highest) to each stock in the universe. Rank is calculated by evaluating each of the stocks factors and combining them into a …
Issuu5mon
Other notable companies that will make an in on the Nasdaq Q-50 index include Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), Groupon Inc (NASDAQ ... 100 index would have propelled the company’s stock immensely. Its …
U.S. stock market report [.N] 1007 ET 11Dec2008-Baidu.com cuts rev ... Shares of Onxy Pharmaceuticals ONXX.O rallied on Thursday after the company was upgraded to overweight from neutral at JPMorgan, which cited positive results from …